SE0201544D0 - Novel compounds and thier use - Google Patents

Novel compounds and thier use

Info

Publication number
SE0201544D0
SE0201544D0 SE0201544A SE0201544A SE0201544D0 SE 0201544 D0 SE0201544 D0 SE 0201544D0 SE 0201544 A SE0201544 A SE 0201544A SE 0201544 A SE0201544 A SE 0201544A SE 0201544 D0 SE0201544 D0 SE 0201544D0
Authority
SE
Sweden
Prior art keywords
sup
novel compounds
compounds
thier
thier use
Prior art date
Application number
SE0201544A
Other languages
English (en)
Inventor
Bjoern Nilsson
Erik Ringberg
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Priority to SE0201544A priority Critical patent/SE0201544D0/sv
Publication of SE0201544D0 publication Critical patent/SE0201544D0/sv
Priority to JP2004505369A priority patent/JP4865221B2/ja
Priority to NZ536409A priority patent/NZ536409A/en
Priority to EA200401526A priority patent/EA007543B1/ru
Priority to YU99804A priority patent/RS99804A/sr
Priority to MXPA04011437A priority patent/MXPA04011437A/es
Priority to CNB038112493A priority patent/CN1329389C/zh
Priority to US10/440,011 priority patent/US7229997B2/en
Priority to SI200330377T priority patent/SI1506185T1/sl
Priority to KR1020047018539A priority patent/KR20050026702A/ko
Priority to BR0310077-4A priority patent/BR0310077A/pt
Priority to PT03725958T priority patent/PT1506185E/pt
Priority to ZA200408975A priority patent/ZA200408975B/en
Priority to EP03725958A priority patent/EP1506185B1/en
Priority to AT03725958T priority patent/ATE327229T1/de
Priority to PCT/SE2003/000795 priority patent/WO2003097636A1/en
Priority to CA002483619A priority patent/CA2483619A1/en
Priority to DE60305484T priority patent/DE60305484T2/de
Priority to DK03725958T priority patent/DK1506185T3/da
Priority to ES03725958T priority patent/ES2263971T3/es
Priority to AU2003228196A priority patent/AU2003228196B2/en
Priority to IL16497404A priority patent/IL164974A0/xx
Priority to NO20045486A priority patent/NO20045486L/no
Priority to HK06103395A priority patent/HK1084941A1/xx
Priority to CY20061101170T priority patent/CY1105162T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
SE0201544A 2002-05-17 2002-05-17 Novel compounds and thier use SE0201544D0 (sv)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SE0201544A SE0201544D0 (sv) 2002-05-17 2002-05-17 Novel compounds and thier use
AU2003228196A AU2003228196B2 (en) 2002-05-17 2003-05-16 Novel compounds and their use
BR0310077-4A BR0310077A (pt) 2002-05-17 2003-05-16 Novos compostos e sua utilização
ZA200408975A ZA200408975B (en) 2002-05-17 2003-05-16 Novel compounds are their use.
EA200401526A EA007543B1 (ru) 2002-05-17 2003-05-16 Производные 4-(3-трифторметилпиридин-5-ил)пиперазина, фармацевтическая композиция, способы их получения и применение
YU99804A RS99804A (en) 2002-05-17 2003-05-16 Novel compounds and their use
MXPA04011437A MXPA04011437A (es) 2002-05-17 2003-05-16 Nuevos compuestos y su uso.
CNB038112493A CN1329389C (zh) 2002-05-17 2003-05-16 化合物和它们的用途
US10/440,011 US7229997B2 (en) 2002-05-17 2003-05-16 Compounds and their use
SI200330377T SI1506185T1 (sl) 2002-05-17 2003-05-16 Spojine in njihova uporaba kot inhibitorji 5-HT
KR1020047018539A KR20050026702A (ko) 2002-05-17 2003-05-16 신규한 화합물 및 이의 용도
JP2004505369A JP4865221B2 (ja) 2002-05-17 2003-05-16 新規化合物とそれらの使用
PT03725958T PT1506185E (pt) 2002-05-17 2003-05-16 Compostos novos e sua utilizacao
NZ536409A NZ536409A (en) 2002-05-17 2003-05-16 New piperazine compounds and their use in the treatment of serotonin-related disorders
EP03725958A EP1506185B1 (en) 2002-05-17 2003-05-16 Compounds and their use as inhibitors of 5-ht
AT03725958T ATE327229T1 (de) 2002-05-17 2003-05-16 Verbindungen und deren verwendung als 5-ht inhibitore
PCT/SE2003/000795 WO2003097636A1 (en) 2002-05-17 2003-05-16 Novel compounds and their use
CA002483619A CA2483619A1 (en) 2002-05-17 2003-05-16 Novel compounds and their use
DE60305484T DE60305484T2 (de) 2002-05-17 2003-05-16 Verbindungen und deren verwendung als 5-ht inhibitoren
DK03725958T DK1506185T3 (da) 2002-05-17 2003-05-16 Forbindelser og deres anvendelse som 5-HT-inhibitorer
ES03725958T ES2263971T3 (es) 2002-05-17 2003-05-16 Compuestos y su uso como inhibidores de 5-ht.
IL16497404A IL164974A0 (en) 2002-05-17 2004-11-01 Novel compounds and their use
NO20045486A NO20045486L (no) 2002-05-17 2004-12-16 Nye forbindelser og deres anvendelse
HK06103395A HK1084941A1 (en) 2002-05-17 2006-03-17 Compounds and their use
CY20061101170T CY1105162T1 (el) 2002-05-17 2006-08-23 Ενωσεις και η χρηση τους ως αναστολεις 5-ητ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201544A SE0201544D0 (sv) 2002-05-17 2002-05-17 Novel compounds and thier use
US41003802P 2002-09-12 2002-09-12

Publications (1)

Publication Number Publication Date
SE0201544D0 true SE0201544D0 (sv) 2002-05-17

Family

ID=29552452

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201544A SE0201544D0 (sv) 2002-05-17 2002-05-17 Novel compounds and thier use

Country Status (25)

Country Link
US (1) US7229997B2 (sv)
EP (1) EP1506185B1 (sv)
JP (1) JP4865221B2 (sv)
KR (1) KR20050026702A (sv)
CN (1) CN1329389C (sv)
AT (1) ATE327229T1 (sv)
AU (1) AU2003228196B2 (sv)
BR (1) BR0310077A (sv)
CA (1) CA2483619A1 (sv)
CY (1) CY1105162T1 (sv)
DE (1) DE60305484T2 (sv)
DK (1) DK1506185T3 (sv)
EA (1) EA007543B1 (sv)
ES (1) ES2263971T3 (sv)
HK (1) HK1084941A1 (sv)
IL (1) IL164974A0 (sv)
MX (1) MXPA04011437A (sv)
NO (1) NO20045486L (sv)
NZ (1) NZ536409A (sv)
PT (1) PT1506185E (sv)
RS (1) RS99804A (sv)
SE (1) SE0201544D0 (sv)
SI (1) SI1506185T1 (sv)
WO (1) WO2003097636A1 (sv)
ZA (1) ZA200408975B (sv)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
JP5173190B2 (ja) * 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
CN103110635A (zh) * 2005-07-04 2013-05-22 海波因特制药有限责任公司 组胺h3受体拮抗剂
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
BRPI0709163A2 (pt) * 2006-03-24 2011-06-28 Wyeth Corp tratamento da dor
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
NZ571972A (en) * 2006-05-29 2011-09-30 High Point Pharmaceuticals Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
WO2007149728A2 (en) * 2006-06-20 2007-12-27 Alcon Research, Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
WO2008052086A1 (en) * 2006-10-24 2008-05-02 Wyeth Benzodioxane derivatives and uses thereof
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
ES2400710T3 (es) 2007-04-23 2013-04-11 Janssen Pharmaceutica, N.V. Tia(dia)zoles como antagonistas del receptor de dopamina 2 de disociación rápida
US8906921B2 (en) 2007-04-23 2014-12-09 Janssen Pharmaceutica Nv 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
WO2010000456A1 (en) 2008-07-03 2010-01-07 Janssen Pharmaceutica Nv Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
EA019048B1 (ru) * 2008-07-31 2013-12-30 Янссен Фармацевтика Нв Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d-рецепторов дофамина
MY157497A (en) 2009-06-15 2016-06-15 Takeda Pharmaceutical Pyrazinooxazepine derivatives
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
TWI589576B (zh) * 2011-07-15 2017-07-01 諾華公司 氮雜－雙環二芳基醚之鹽類及製造彼等或其前驅物之方法
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078063A (en) * 1976-09-24 1978-03-07 Merck & Co., Inc. Piperazinylpyridines
DE68912282T2 (de) * 1988-11-24 1994-04-28 Akzo Nv 1-[Mono- oder bis(trifluormethyl)-2-pyridinyl]piperazine enthaltende pharmazeutische Zusammensetzungen.
JPH0665203A (ja) * 1992-06-25 1994-03-08 Elf Sanofi ピペラジンのヘテロ環誘導体
EP0580465A1 (fr) * 1992-06-25 1994-01-26 Sanofi Nouvelle utilisation thérapeutique d'hétérocyclyl-pipérazines comme 5-HT3 agonistes et nouveaux dérivés
SE9202265D0 (sv) * 1992-07-31 1992-07-31 Kabi Pharmacia Ab Novel- pyridyl and pyrimidylpiperazine derivatives
JPH0797370A (ja) * 1993-09-29 1995-04-11 Asahi Chem Ind Co Ltd ２−アルコキシピラジン誘導体およびその用途
WO1998033504A1 (en) * 1997-02-03 1998-08-06 Akzo Nobel N.V. Treatment of urinary incontinence
JP3989102B2 (ja) * 1997-10-02 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリジン誘導体
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
NZ525700A (en) * 2000-11-20 2004-12-24 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor
US6498184B2 (en) * 2000-12-05 2002-12-24 Akzo Nobel N.V. Serotonergic compound for a method of treatment of hot flushes in post-menopausal women
EP1213017A3 (en) * 2000-12-05 2003-11-12 Akzo Nobel N.V. Use of a 5-HT2C receptor agonist for the treatment of hot flushes

Also Published As

Publication number Publication date
DE60305484D1 (de) 2006-06-29
ZA200408975B (en) 2005-11-14
EP1506185B1 (en) 2006-05-24
NO20045486L (no) 2005-02-02
CA2483619A1 (en) 2003-11-27
RS99804A (en) 2006-12-15
SI1506185T1 (sl) 2006-10-31
ATE327229T1 (de) 2006-06-15
KR20050026702A (ko) 2005-03-15
US20030232814A1 (en) 2003-12-18
CN1701068A (zh) 2005-11-23
DE60305484T2 (de) 2006-11-09
EA007543B1 (ru) 2006-10-27
DK1506185T3 (da) 2006-10-02
CY1105162T1 (el) 2010-03-03
AU2003228196A1 (en) 2003-12-02
PT1506185E (pt) 2006-10-31
WO2003097636A1 (en) 2003-11-27
ES2263971T3 (es) 2006-12-16
AU2003228196B2 (en) 2009-12-17
JP2005529926A (ja) 2005-10-06
HK1084941A1 (en) 2006-08-11
US7229997B2 (en) 2007-06-12
NZ536409A (en) 2007-11-30
EA200401526A1 (ru) 2005-04-28
IL164974A0 (en) 2005-12-18
MXPA04011437A (es) 2005-02-17
EP1506185A1 (en) 2005-02-16
JP4865221B2 (ja) 2012-02-01
BR0310077A (pt) 2005-02-22
CN1329389C (zh) 2007-08-01

Similar Documents

Publication Publication Date Title
SE0201544D0 (sv) Novel compounds and thier use
IS6658A (is) Ný efnasambönd
SE0302760D0 (sv) New compounds
SE0001899D0 (sv) New compounds
PT1263725E (pt) Novos compostos
IS2376B (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
SE0103836D0 (sv) Novel compounds
ATE316083T1 (de) Adamantanderivate
SE0300480D0 (sv) Novel compounds
SE0302139D0 (sv) Novel compounds
ATE386725T1 (de) Heterocyclylverbindungen
TW200604197A (en) New compounds
NO20020282L (no) Nytt difenyl-piperidinderivat
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0101038D0 (sv) Novel compounds
DE602004031410D1 (de) Inden derivate als pharmazeutika
SE0203303D0 (sv) Novel Compounds
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0303280D0 (sv) Novel compounds
SE0302755D0 (sv) Novel compounds
SE0202693D0 (sv) Compounds
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
SE0403118D0 (sv) New compounds 2
SE0403117D0 (sv) New compounds 1
ATE374751T1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern